No definition available.
Localized skin eruption due to drugs and medicaments
LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
480 |
4. Check minimum number of eventsNone |
480 |
5. Include endpointsNone |
480 |
6. Filter based on genotype QC (FinnGen only) |
437 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Localized skin eruption due to drugs and medicaments
based on the number of shared cases.
Similar with more cases:
- Dermatitis due to substances taken internally
- Dermatitis and eczema
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2626 | 1498 | 1115 |
| Only index persons | 2347 | 1368 | 979 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 51.43 | 54.02 | 47.91 |
| Only index persons | 52.21 | 54.10 | 49.55 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 437 | 276 | 161 |
| Unadjusted period prevalence (%) | 0.09 | 0.10 | 0.07 |
| Median age at first event (years) | 56.50 | 53.26 | 62.06 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 452
- Matched controls
- 4520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L27.1
ICD-10 Finland
Localized skin eruption due to drugs and medicaments
4503599627370496.0
307.7
451
*
H02AB06
ATC
prednisolone; systemic
4.6
49.6
324
1612
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
5.1
42.5
106
256
XQ800
NOMESCO Finland
Prick test
5.5
38.7
84
179
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.1
25.7
151
638
XQ802
NOMESCO Finland
Epicutan test
5.8
24.6
47
88
D07AC01
ATC
betamethasone; topical
2.7
22.7
219
1183
R06AE07
ATC
cetirizine; oral
2.6
21.8
254
1495
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.7
20.4
71
215
E0000UV, ,
ATC
2.5
19.5
238
1407
XQ820
NOMESCO Finland
Exposure to medicinal substance
48.3
19.4
23
5
R06AX27
ATC
desloratadine; oral
2.5
19.1
179
937
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.4
18.9
257
1589
L27.0
ICD-10 Finland
Generalized skin eruption due to drugs and medicaments
15.0
18.9
31
22
T78.4
ICD-10 Finland
Allergy, unspecified
4.7
17.2
42
97
J01MA02
ATC
ciprofloxacin; systemic
2.3
16.2
207
1221
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
15.1
154
822
J01FF01
ATC
clindamycin; systemic
2.3
14.5
152
817
N02AX02
ATC
tramadol; systemic, rectal
2.2
14.5
224
1409
A02BC02
ATC
pantoprazole; systemic
2.3
14.1
335
2487
A03FA01
ATC
metoclopramide; systemic, rectal
2.3
13.9
135
701
R06AE09
ATC
levocetirizine; oral
2.6
13.6
92
405
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
6.2
13.2
23
39
XQ801
NOMESCO Finland
Intracutantest
17.4
13.1
20
12
J01AA02
ATC
doxycycline; systemic
2.5
12.8
374
2963
L50.0
ICD-10 Finland
Allergic urticaria
5.1
12.3
26
53
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
3.3
12.1
48
157
J45.9
ICD-10 Finland
Asthma, unspecified
2.3
12.1
114
581
D07BA04
ATC
hydrocortisone and antiseptics; topical
2.9
12.1
61
230
A02BC05
ATC
esomeprazole; systemic
2.0
11.9
207
1333
A04AA01
ATC
ondansetron; systemic, rectal
3.0
11.9
56
203
D07AD01
ATC
clobetasol; topical
2.4
11.7
95
453
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.1
11.4
145
830
M13.9
ICD-10 Finland
Arthritis, unspecified
3.0
11.4
52
185
N03AX16
ATC
[U] pregabalin
2.2
11.3
124
670
UJF32
NOMESCO Finland
Coloscopy
2.1
11.3
135
755
R50.9
ICD-10 Finland
Fever, unspecified
2.4
11.2
91
433
D07AB02
ATC
hydrocortisone butyrate; topical
2.1
11.2
157
931
H02AB02
ATC
dexamethasone; systemic
2.6
10.9
69
292
J02AC01
ATC
fluconazole; systemic
1.9
10.4
200
1315
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
10.4
118
643
J46
ICD-10 Finland
Status asthmaticus
4.9
10.4
23
49
H02AB07
ATC
prednisone; oral
2.4
10.3
77
353
J01DB01
ATC
cefalexin; oral
2.5
10.2
392
3271
J01MA12
ATC
levofloxacin; systemic
2.2
10.1
94
473
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.6
10.0
64
272
N48.1
ICD-10 Finland
Balanoposthitis
5.5
9.7
19
36
L04AX03
ATC
methotrexate; systemic
2.6
9.6
62
265
R02
ICPC
Shortness of breath/dyspnoea
2.3
9.5
77
365
L50.9
ICD-10 Finland
Urticaria, unspecified
3.5
9.5
33
99
A02BC03
ATC
lansoprazole; oral
2.0
9.4
145
879
WZC30
NOMESCO Finland
Teaching
2.2
9.4
92
472
R03BA05
ATC
fluticasone; inhalant
2.1
9.4
103
553
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.1
9.4
108
591
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
2.3
9.3
77
369
M54.5
ICD-10 Finland
Low back pain
1.9
9.2
186
1231
D07AC13
ATC
mometasone; topical
1.9
9.2
143
870
UDC00
NOMESCO Finland
Ear microscopy
2.7
8.8
50
200
X59
ICD-10 Finland
Exposure to unspecified factor
2.1
8.7
102
559
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.0
8.7
106
590
S29
ICPC
Skin symptom/complaint other
2.0
8.7
110
621
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
8.7
162
1042
J05AB01
ATC
aciclovir; systemic
2.0
8.6
120
702
R03AC02
ATC
salbutamol; inhalant
1.8
8.5
272
2056
E000001, ,
ATC
2.0
8.5
102
565
AA1AD
NOMESCO Finland
CT of head and brain
1.9
8.4
138
850
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
8.4
72
349
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.3
8.3
72
351
S18
ICPC
Laceration/cut
1.8
8.2
227
1636
R03DC03
ATC
montelukast; oral
2.1
8.2
92
496
D07BC01
ATC
betamethasone and antiseptics; topical
2.4
8.1
61
279
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.4
8.1
61
279
T88.7
ICD-10 Finland
Unspecified adverse effect of drug or medicament
6.5
8.1
20
32
N05CF01
ATC
zopiclone; oral
1.8
8.0
154
996
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
3.0
7.9
36
128
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.0
7.9
101
571
H02AB04
ATC
methylprednisolone; systemic
2.2
7.8
75
381
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
4.1
7.7
21
53
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.8
7.7
183
1257
D07AB08
ATC
desonide; topical
2.3
7.7
62
293
L03AA13
ATC
pegfilgrastim; parenteral
3.1
7.7
32
108
R03BA02
ATC
budesonide; inhalant
2.0
7.7
97
546
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.8
7.6
139
881
N05BA04
ATC
oxazepam; oral
1.8
7.6
134
840
J01FA09
ATC
clarithromycin; systemic
1.8
7.6
155
1016
R00.2
ICD-10 Finland
Palpitations
2.5
7.5
50
216
TQW80
NOMESCO Finland
Local dermatologic skincare
4.4
7.5
19
45
A06AC01
ATC
ispaghula (psylla seeds); oral
1.9
7.5
129
802
L17
ICPC
Foot/toe symptom/complaint
1.8
7.5
154
1011
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.2
7.5
65
316
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
2.6
7.5
44
179
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
1.9
7.5
123
755
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.9
7.5
122
747
M79.6
ICD-10 Finland
Pain in limb
1.7
7.4
214
1547
C01CA24
ATC
epinephrine; parenteral
2.6
7.4
43
174
ZX120
NOMESCO Finland
Intravenous
2.4
7.4
52
231
R03AK07
ATC
formoterol and budesonide; inhalant
1.9
7.4
109
646
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.7
7.4
254
1929
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
4.1
7.2
20
51
N03AX12
ATC
[U] gabapentin; oral
2.0
7.2
86
473
R06AX13
ATC
loratadine; oral
2.0
7.1
82
445
J01FA10
ATC
azithromycin; systemic
1.7
7.1
276
2158
J01DA01
ATC
[U] cefalexin
1.7
7.1
283
2228
N02BE01
ATC
paracetamol; systemic, rectal
2.4
7.0
411
3643
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
4.1
7.0
19
48
B01AB05
ATC
enoxaparin; parenteral
1.8
7.0
150
996
C09CA06
ATC
candesartan; oral
1.8
6.9
116
714
N06AX21
ATC
duloxetine; oral
2.1
6.9
67
341
R01BA52
ATC
pseudoephedrine, combinations; oral
1.8
6.9
140
913
J01FA06
ATC
roxithromycin; oral
1.7
6.9
182
1279
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
2.9
6.9
33
121
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
6.8
121
758
R01AD09
ATC
mometasone; nasal
1.7
6.8
219
1621
UKC02
NOMESCO Finland
Cystoscopy
2.1
6.7
72
380
L08
ICPC
Shoulder symptom/complaint
1.8
6.7
115
712
XG410
NOMESCO Finland
Flow-volume spirometry
3.2
6.7
26
84
TPH04
NOMESCO Finland
Cathetrisation of vein
1.9
6.7
106
641
R06.0
ICD-10 Finland
Dyspnoea
1.8
6.6
132
855
N05BA01
ATC
diazepam; systemic, rectal
2.1
6.6
67
347
A02BC01
ATC
omeprazole; systemic
1.8
6.6
126
807
ZXE10
NOMESCO Finland
More than one and less than three hours
1.7
6.6
162
1114
R51.80
ICD-10 Finland
Headache
1.9
6.6
90
519
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
3.8
6.5
20
55
D02AX
ATC
Other emollients and protectives
3.6
6.5
21
60
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.7
6.4
194
1405
R96
ICPC
Asthma
2.2
6.4
56
273
N02AJ06
ATC
codeine and paracetamol; systemic
1.7
6.4
208
1535
R01AD08
ATC
fluticasone; nasal
1.7
6.4
140
931
SPAT1260
SPAT
Consultation of another employee
1.9
6.4
86
493
S09
ICPC
Infected finger/toe
3.6
6.4
21
61
R07.4
ICD-10 Finland
Chest pain, unspecified
1.7
6.4
135
889
SPAT1301
SPAT
No procedures
1.7
6.3
144
966
L01
ICPC
Neck symptom/complaint
1.9
6.3
86
494
ZXE00
NOMESCO Finland
One hour or less
1.7
6.3
179
1275
M54.4
ICD-10 Finland
Lumbago with sciatica
1.9
6.3
94
557
J45.8
ICD-10 Finland
Mixed asthma
3.6
6.2
20
57
R06AX22
ATC
ebastine; oral
1.9
6.2
87
505
A08.4
ICD-10 Finland
Viral intestinal infection, unspecified
3.1
6.2
25
83
M03BX02
ATC
tizanidine; oral
1.7
6.1
283
2272
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.2
6.1
55
271
UDH02
NOMESCO Finland
Rhinopharyngoscopy
2.5
6.1
38
159
SPAT1263
SPAT
Sampling
1.6
6.1
190
1382
A07AA02
ATC
nystatin; oral
2.7
6.1
32
123
H66.9
ICD-10 Finland
Otitis media, unspecified
2.5
6.1
40
172
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
2.1
6.1
57
286
L04AA13
ATC
[U] leflunomide
4.0
6.0
17
44
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
282
1773
2.57
20.62
6.7
6.2
1.21
1.21
mmol/l
0.06
265
1649
338
2333
2.78
20.13
15.7
10.2
4.28
4.07
e9/l
0.87
310
2044
298
1982
2.48
18.38
7.9
7.1
1.22
1.21
mmol/l
0.39
245
1722
394
3048
3.28
17.15
13.9
8.4
80.39
79.51
u/l
0.15
376
2876
259
1698
2.23
15.40
7.6
5.0
35.51
35.97
g/l
0.70
242
1607
265
1789
2.16
14.18
18.0
12.8
1.22
1.21
inr
0.21
235
1481
301
2140
2.22
14.05
9.8
6.7
10.96
11.16
umol/l
0.07
285
2043
373
3008
2.37
11.25
7.0
4.5
13.02
11.37
mm/h
1.27
352
2807
110
578
2.19
10.71
3.3
2.6
89.66
121.67
ug/g
1.18
83
451
310
2366
1.99
10.25
6.4
4.8
6.51
6.62
mmol/l
0.51
297
2232
163
1005
1.97
10.25
3.9
4.0
92.91
91.56
%
0.27
155
987
140
824
2.01
10.01
1.4
1.3
15.33
32.95
iu/ml
3.33
49
262
257
1854
1.90
9.94
3.2
2.5
76.31
76.41
nmol/l
0.02
233
1670
114
626
2.10
9.83
2.9
2.3
2.42
2.36
g/l
0.55
104
579
197
1312
1.89
9.71
3.8
2.6
53.95
63.69
u/l
1.12
172
1226
22
48
4.77
9.63
1.6
1.9
90.72
90.02
%
0.20
22
48
119
670
2.05
9.57
3.0
2.4
12.91
13.39
umol/l
0.30
112
626
180
1170
1.89
9.52
1.9
1.7
21.22
20.78
nmol/l
0.15
158
989
116
651
2.05
9.39
4.3
3.6
0.81
0.82
mmol/l
0.08
110
620
184
1220
1.86
9.03
2.1
2.2
205.12
247.90
u/l
0.22
173
1160
95
503
2.13
8.94
5.7
5.9
1.03
1.04
mmol/l
0.24
88
468
243
1775
1.80
8.52
2.4
2.0
98.73
96.74
pmol/l
0.26
139
926
103
578
2.01
8.24
3.1
2.4
22.16
22.98
%
0.24
96
545
199
1383
1.78
8.16
5.9
3.4
2.34
2.36
mmol/l
1.46
186
1253
106
605
1.98
8.07
1.7
2.1
29.33
29.23
s
0.08
106
588
133
821
1.88
8.01
1.9
1.7
447.91
24029207.48
pmol/l
0.72
107
695
67
322
2.27
7.97
4.9
3.9
1.22
1.23
mmol/l
1.03
59
283
106
609
1.97
7.91
1.8
1.7
1281.46
1208.31
nmol/l
0.33
76
460
46
187
2.63
7.86
2.0
2.2
8.17
6.13
iu/ml
0.18
13
47
268
2044
1.76
7.84
4.1
3.0
115.10
106.22
ug/l
0.24
248
1916
280
2163
1.77
7.83
5.4
3.9
0.00
0.00
estimate
-0.00
78
474
73
369
2.17
7.67
2.8
2.4
0.21
0.22
g/l
0.52
68
349
281
2190
1.75
7.45
5.4
3.9
0.00
3.40
estimate
0.50
78
478
282
2207
1.74
7.30
5.5
3.9
0.00
0.68
estimate
0.53
74
458
432
3912
3.36
7.26
28.6
15.4
19.43
22.47
mg/l
1.72
399
3225
78
418
2.05
7.02
3.7
3.2
—
—
—
0
0
325
2665
1.78
6.96
6.9
4.6
123.17
535.19
e6/l
—
6
47
167
1146
1.73
6.88
3.2
3.1
1194.40
1145.85
ng/l
0.08
141
977
168
1156
1.72
6.84
4.3
3.0
0.43
0.41
e6/l
0.05
135
817
174
1209
1.71
6.84
5.4
4.0
0.00
0.00
estimate
0.50
74
452
58
282
2.21
6.69
1.6
1.6
—
—
—
0
0
121
764
1.80
6.62
1.4
1.3
35.58
12.38
u/ml
0.32
50
303
140
924
1.75
6.57
3.7
2.6
5.60
5.97
e6/l
0.11
128
840
21
60
3.62
6.51
1.7
1.6
—
—
—
0
0
13
16
8.33
6.37
1.2
2.3
—
0.86
—
0
5
49
227
2.30
6.34
3.5
3.7
1.63
1.34
mmol/l
0.24
32
170
249
1929
1.65
6.29
3.4
2.8
—
—
estimate
—
0
0
143
965
1.70
6.13
1.8
1.8
1.16
1.27
mg/l
0.13
105
767
204
1511
1.64
6.11
4.8
3.7
22.01
73.57
ng/l
0.75
144
1056
20
58
3.56
6.08
1.6
1.6
—
—
—
0
0
365
3144
1.84
6.08
6.4
4.5
14.73
14.67
pmol/l
0.19
344
2886
15
25
6.17
6.04
2.5
2.8
—
—
—
0
0
152
1051
1.67
5.92
3.2
2.9
323.80
337.10
umol/l
0.92
133
927
221
1684
1.61
5.80
5.3
3.7
1.47
0.02
estimate
0.48
68
410
62
329
2.03
5.71
7.3
7.4
8.86
9.01
mmol/l
0.07
57
318
185
1356
1.62
5.66
4.6
3.1
63.81
92.11
e6/l
0.21
150
1014
77
442
1.89
5.65
3.8
4.7
214.77
267.13
u/l
1.94
71
422
103
649
1.76
5.59
2.3
2.0
—
—
—
0
0
18
52
3.56
5.51
1.2
1.3
—
—
—
0
0
151
1065
1.63
5.34
3.3
2.2
2.91
2.90
mg/l
0.01
133
925
11
15
7.49
5.17
1.5
3.0
735.00
835.73
u/ml
0.14
11
15
324
2747
1.63
5.17
4.2
3.4
52.47
46.39
u/l
0.57
303
2614
23
82
2.90
5.06
1.4
1.6
—
—
—
0
0
311
2620
1.60
5.00
3.6
3.3
—
—
—
0
0
30
124
2.52
4.99
1.5
1.7
—
—
—
0
0
60
331
1.94
4.95
1.5
1.3
118.30
155.34
u/ml
0.24
22
142
28
114
2.55
4.81
1.3
1.1
—
—
—
0
0
22
79
2.88
4.78
1.6
1.7
—
—
—
0
0
31
133
2.43
4.78
1.6
1.3
7.77
6.70
u/ml
—
6
23
15
35
4.40
4.67
1.7
1.5
—
—
—
0
0
66
384
1.84
4.63
2.4
2.3
30.88
30.83
u/l
0.01
57
317
404
3673
1.94
4.61
7.7
5.5
1.89
1.88
mu/l
0.05
381
3417
29
123
2.45
4.59
1.5
1.7
—
—
—
0
0
25
100
2.59
4.46
1.4
1.6
—
—
—
0
0
150
1095
1.55
4.45
1.6
1.3
1.44
2.10
u/ml
0.36
45
315
27
113
2.48
4.40
1.3
1.1
—
—
—
0
0
26
107
2.52
4.38
2.0
1.5
—
—
—
0
0
12
24
5.11
4.34
1.5
1.5
—
—
—
0
0
16
51
3.22
4.25
1.8
1.3
—
—
—
0
0
12
25
4.90
4.21
1.6
1.6
—
—
—
0
0
41
211
2.04
4.12
1.6
1.3
—
—
—
0
0
66
399
1.77
4.08
6.5
4.3
10.70
35.77
ug/l
0.63
53
322
28
125
2.32
3.99
1.5
2.2
10.40
11.39
mg/l
0.27
28
119
12
27
4.54
3.96
1.5
1.6
—
—
—
0
0
165
1261
1.49
3.84
4.6
3.3
4.19
0.07
estimate
0.51
62
392
70
439
1.70
3.80
7.4
7.7
1.75
0.97
mmol/l
1.02
59
383
183
1432
1.47
3.77
3.9
3.3
29.08
32.38
u/l
0.90
171
1364
121
875
1.52
3.65
1.9
1.6
—
—
—
0
0
28
131
2.21
3.59
1.5
1.4
12.00
9.53
u/l
0.36
23
104
27
125
2.23
3.55
2.9
2.4
0.00
1.07
g/l
1.99
22
108
27
126
2.22
3.49
3.4
3.9
178.23
95.56
mg/l
0.22
20
109
27
126
2.22
3.49
3.4
3.9
30.85
44.74
mg/l
0.39
21
108
23
100
2.37
3.49
1.1
1.3
—
—
—
0
0
60
370
1.72
3.47
3.6
4.0
2.17
1.73
mmol/l
0.35
53
318
31
155
2.07
3.39
2.5
1.9
0.83
1.10
ug/l
0.25
25
139
398
3673
1.70
3.35
7.0
6.3
38.82
39.03
mmol/mol
0.19
365
3464
14
48
2.98
3.33
1.3
1.2
—
—
—
0
0
37
199
1.94
3.32
1.8
1.3
—
—
—
0
0
70
456
1.63
3.30
2.3
1.9
—
—
—
0
0
18
72
2.56
3.25
1.5
1.7
—
—
—
0
0
131
985
1.46
3.23
3.1
2.3
—
—
—
0
0
21
91
2.37
3.22
1.4
1.6
—
—
—
0
0
53
325
1.71
3.13
1.3
1.4
—
—
—
0
0
28
139
2.08
3.13
3.2
3.1
—
—
—
0
0
73
487
1.60
3.12
2.2
1.8
—
—
—
0
0
25
119
2.17
3.10
1.2
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
100
2.26
3.04
2.5
2.7
0.47
0.36
iu/ml
0.49
14
54
24
114
2.17
3.00
1.9
1.3
—
—
—
0
0
49
298
1.72
2.99
3.5
4.0
81.19
77.94
ng/l
0.09
37
265
432
4120
2.10
2.77
20.8
12.1
24.51
25.72
u/l
1.15
422
4018
23
112
2.11
2.72
3.7
3.6
29.23
2.51
ratio
0.45
14
64
35
199
1.82
2.69
3.5
2.4
921.13
4690.99
u/l
1.22
11
80
78
549
1.51
2.64
7.0
6.6
103.22
104.05
mmol/l
0.70
78
549
74
519
1.51
2.54
1.7
1.8
1.52
1.45
%
0.29
58
452
22
109
2.07
2.50
1.4
1.2
—
46.22
—
0
15
403
3785
1.60
2.49
26.9
14.7
83.54
83.60
ml/min/173m2
0.02
391
3495
24
124
1.99
2.45
1.3
1.3
—
—
—
0
0
95
707
1.44
2.42
3.8
2.7
1.03
0.87
e6/l
0.22
52
356
8
22
3.68
2.37
6.6
3.0
2.13
1.18
%
—
8
22
25
133
1.93
2.36
1.3
1.3
—
—
—
0
0
37
225
1.70
2.29
1.3
1.4
16.64
24.34
iu/l
0.80
30
191
27
152
1.83
2.17
2.0
1.6
—
—
—
0
0
87
650
1.42
2.17
3.9
2.8
3.89
2.52
e6/l
0.66
44
300
34
209
1.68
2.04
2.0
1.6
—
—
—
0
0
67
484
1.45
2.00
2.4
3.0
12.09
7.61
umol/l
0.57
61
423
165
1380
1.31
1.98
3.8
3.5
6.87
7.80
mmol/l
2.20
130
1173
6
16
3.79
1.94
5.2
6.6
—
—
—
0
0
14
67
2.12
1.77
1.1
1.2
—
—
—
0
0
14
67
2.12
1.77
1.1
1.2
—
—
—
0
0
359
3357
1.34
1.72
32.0
19.1
13.74
13.56
%
1.81
359
3329
92
721
1.35
1.72
2.0
1.5
—
—
—
0
0
17
89
1.95
1.72
1.4
1.7
—
—
—
0
0
17
90
1.92
1.67
1.1
1.2
0.07
2.30
u/ml
—
8
56
5
15
3.36
1.52
1.0
1.9
—
—
—
0
0
5
15
3.36
1.52
1.0
1.9
—
—
—
0
0
23
140
1.68
1.48
1.7
1.7
—
—
—
0
0
93
747
1.31
1.47
4.2
3.7
287.41
309.69
ng/l
0.03
71
553
19
110
1.76
1.45
1.7
2.9
0.22
1.79
index
—
9
60
6
22
2.75
1.44
1.0
1.0
—
—
—
0
0
150
1289
1.24
1.38
4.8
4.3
11.20
9.25
mg/mmol
0.19
85
805
115
961
1.26
1.34
5.5
3.9
1.02
1.02
kg/l
0.73
74
639
73
575
1.32
1.33
2.6
2.3
—
—
—
0
0
16
91
1.79
1.30
1.9
7.1
—
356.13
—
0
15
395
3785
1.35
1.30
6.1
5.0
5.90
5.89
mmol/l
0.03
367
3506
8
35
2.31
1.27
1.6
2.3
—
—
—
0
0
19
116
1.67
1.23
1.3
1.3
—
—
—
0
0
7
142
0.49
1.23
1.0
1.1
1.44
1.58
g/l
—
7
142
23
149
1.57
1.19
2.0
1.6
—
—
—
0
0
12
64
1.90
1.19
1.2
1.4
—
—
—
0
0
8
38
2.12
1.19
1.0
1.7
—
—
—
0
0
16
94
1.73
1.19
1.8
1.3
2.55
6.22
e6/l
0.61
11
73
10
50
2.02
1.17
1.3
1.8
—
—
—
0
0
43
320
1.38
1.14
4.2
2.6
59.29
67.21
ml/min/173m2
0.63
17
137
33
234
1.44
1.14
1.1
1.0
—
—
—
0
0
66
526
1.30
1.12
2.6
2.1
—
—
—
0
0
23
153
1.53
1.08
1.5
1.6
16.64
9.48
u/ml
—
5
33
10
52
1.94
1.07
1.0
1.1
—
—
—
0
0
8
147
0.54
1.05
1.1
1.1
0.82
0.88
g/l
—
8
147
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
22
2.29
1.03
1.4
1.6
100.60
133.95
%
—
5
22
191
1728
1.18
0.98
2.1
2.0
1.36
1.34
mmol/l
0.13
147
1458
7
36
1.96
0.97
1.0
1.1
—
—
—
0
0
60
483
1.28
0.96
5.8
4.8
31.82
31.74
%
0.02
44
321
14
85
1.67
0.95
7.0
2.9
10.24
8.88
pmol/l
0.24
14
85
44
341
1.32
0.93
3.5
2.1
—
—
—
0
0
18
118
1.55
0.92
1.3
1.4
324.75
307.99
ug/g
—
8
66
21
144
1.48
0.89
2.4
2.0
—
—
—
0
0
6
30
2.01
0.87
1.7
1.2
119.50
106.17
pmol/l
—
6
30
24
170
1.43
0.87
2.5
3.3
24.95
25.18
mmol/l
0.21
24
164
123
1083
1.19
0.86
6.5
5.4
2.29
2.39
ug/l
0.07
105
976
37
286
1.32
0.81
3.2
2.0
—
—
—
0
0
0
24
0.00
0.79
0.0
1.5
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
6
33
1.83
0.79
1.2
1.0
—
—
—
0
0
6
33
1.83
0.79
1.2
2.9
297.67
881.73
mg
—
6
33
24
176
1.38
0.74
2.0
1.6
2.87
3.18
mg/l
0.14
17
132
5
25
2.01
0.73
1.4
1.3
186.60
167.89
pmol/l
—
5
25
7
39
1.81
0.72
1.4
1.7
—
—
—
0
0
7
39
1.81
0.72
1.4
1.7
—
—
—
0
0
7
39
1.81
0.72
1.4
1.7
—
—
—
0
0
19
134
1.44
0.72
2.3
1.8
—
—
—
0
0
7
40
1.76
0.71
1.0
1.1
—
—
—
0
0
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
11
69
1.61
0.69
1.3
1.1
1.02
1.83
eliau/ml
—
5
33
9
59
1.54
0.68
3.7
1.8
—
—
—
0
0
5
27
1.86
0.68
1.0
1.0
—
—
—
0
0
7
43
1.64
0.67
1.4
1.9
—
—
—
0
0
17
120
1.43
0.65
1.7
1.9
45.24
40.13
nmol/l
0.34
17
115
7
44
1.60
0.65
1.1
1.4
—
—
—
0
0
7
44
1.60
0.65
1.1
1.4
—
—
—
0
0
14
96
1.47
0.62
1.1
1.2
—
—
—
0
0
50
420
1.21
0.60
11.2
6.3
—
—
—
0
0
10
65
1.55
0.56
1.1
1.1
—
—
—
0
0
6
37
1.63
0.55
1.2
1.4
—
—
—
0
0
27
214
1.28
0.54
1.6
1.5
0.31
0.32
mg/l
0.02
12
90
6
39
1.55
0.53
1.3
3.5
1.43
6.92
nmol/l
—
6
39
396
3874
1.18
0.52
5.9
5.1
4.65
4.65
mmol/l
0.00
369
3638
7
45
1.56
0.49
1.0
1.4
—
—
—
0
0
7
45
1.56
0.49
1.1
1.4
—
—
—
0
0
7
46
1.53
0.48
1.1
1.4
—
—
—
0
0
7
46
1.53
0.48
1.1
1.4
—
—
—
0
0
378
3692
1.15
0.47
5.0
4.2
1.35
1.27
mmol/l
1.18
346
3436
16
120
1.35
0.46
2.2
2.1
2.31
3.59
iu/l
—
5
48
393
3858
1.14
0.40
5.8
5.0
1.47
1.48
mmol/l
0.16
362
3606
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
5
35
1.43
0.39
1.0
1.2
—
—
—
0
0
73
660
1.13
0.38
3.3
3.1
0.72
0.74
ug/l
0.07
53
415
13
169
0.76
0.37
1.6
1.4
—
—
—
0
0
15
116
1.30
0.37
1.3
1.2
—
—
—
0
0
10
133
0.75
0.34
1.7
1.5
—
—
—
0
0
7
52
1.35
0.31
1.1
1.1
1.66
1.45
g/l
—
7
47
7
54
1.30
0.30
1.4
1.2
—
—
—
0
0
7
55
1.28
0.30
1.0
1.3
7.20
7.19
mmol/l
—
7
46
94
877
1.09
0.29
4.8
4.6
23.22
21.01
%
0.72
49
404
11
86
1.29
0.26
2.0
1.4
—
—
—
0
0
5
40
1.25
0.22
2.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
6
51
1.18
0.19
1.3
1.0
—
—
—
0
0
11
90
1.23
0.19
1.7
1.5
—
—
—
0
0
396
3920
1.08
0.19
6.5
5.8
2.71
2.72
mmol/l
0.12
366
3673
7
61
1.15
0.17
1.3
1.3
—
—
—
0
0
8
68
1.18
0.16
1.9
1.4
—
—
—
0
0
32
345
0.92
0.13
1.9
1.8
3.45
3.43
mmol/l
0.04
24
255
14
123
1.14
0.12
1.6
1.7
—
—
—
0
0
15
167
0.89
0.11
1.3
1.4
176.99
250.75
miu/ml
—
5
87
5
46
1.09
0.09
1.6
1.2
—
—
—
0
0
12
108
1.11
0.07
1.4
1.8
—
—
—
0
0
44
455
0.96
0.05
2.4
2.0
3.16
3.43
ratio
0.75
33
365
15
141
1.07
0.03
1.5
1.4
—
—
—
0
0
10
92
1.09
0.03
1.7
1.5
45.34
52.13
ug/l
—
10
92
10
97
1.03
0.00
1.8
2.0
138.60
227.36
pmol/l
—
10
87
0
7
0.00
0.00
0.0
3.1
—
53.43
—
0
7
0
7
0.00
0.00
0.0
1.1
—
1.16
—
0
7
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
7.7
—
5.89
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
52.40
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM | 1.557 [1.26, 1.93] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.626 |
During the follow-up period (1.1.1998 — 31.12.2019), 246 out of 1248 females with LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM | 1.561 [1.26, 1.93] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.027 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 969 males with LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM died.
Mortality risk
Mortality risk for people of age
years, who have LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.143% | 0.415% |
| 5 | 1.089% | 2.227% |
| 10 | 2.717% | 5.267% |
| 15 | 4.883% | 9.734% |
| 20 | 8.541% | 15.853% |
Relationships between endpoints
↥Index endpoint: LOCALIZED_SKIN_ERUPT_DRUGS_MEDICAM – Localized skin eruption due to drugs and medicaments
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data